Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE: ADPJ-secr vs EUS-FNA for IPMN
NCT05914077Phase 3Unknown
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr at 30 months. Status: unknown.
Beyond the preview
Go deeper on NCT05914077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914077.